Contouring with FLAIR: Targeting Peritumoral Edema (and Beyond) in Glioblastoma [0.03%]
使用FLAIR进行轮廓处理：在胶质母细胞瘤中针对周围肿瘤性水肿（及更多）
Jerome M Karp,Tim J Kruser
Jerome M Karp
Time to Target [0.03%]
达到目标所需时间
Sarah Dooley,Jessica M Frakes
Sarah Dooley
Michael Chisam,Manisha Palta
Michael Chisam
Unresectable Pancreatic Adenocarcinoma: Evidence-Based Medicine or a Gut Feeling? [0.03%]
不能切除的胰腺腺癌：基于证据的医学还是直觉？
John G Roubil,Emma C Fields
John G Roubil
Precision Over Tradition: Transforming Prostate Cancer Treatment with Stereotactic Radiation Therapy [0.03%]
精准超越传统：用立体定向放射治疗变革前列腺癌治疗
Priyamvada Maitre,Nicholas G Zaorsky,Robert T Dess et al.
Priyamvada Maitre et al.
Establishing a deep learning model that integrates pre- and mid-treatment computed tomography to predict treatment response for non-small cell lung cancer [0.03%]
建立深度学习模型以整合非小细胞肺癌治疗前后及中期的计算机断层扫描影像来预测治疗反应
Xuming Chen,Fanrui Meng,Ping Zhang et al.
Xuming Chen et al.
Background: Patients with identical stages or similar tumor volumes can vary significantly in their responses to radiotherapy (RT) due to individual characteristics, making personalized RT for non-small cell lung cancer (...
Long Term Results of a Phase II Study of Adjuvant Proton Radiotherapy for Node-Positive Cancer of the Uterus and Cervix: Proton Radiation for Uterine/Cervical Cancer [0.03%]
子宫和宫颈淋巴结阳性癌症术后质子放射治疗的II期临床试验的长期结果：用于子宫/宫颈癌的质子放疗
Andrea L Russo,Nicolas Depauw,Nora K Horick et al.
Andrea L Russo et al.
Purpose/objective(s): Patients with node-positive (LN+) uterine or cervical cancer often require post-operative radiation (RT) to the pelvis and para-aortic nodes. A prospective phase II study was conducted to evaluate th...
Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities from Large Brain Metastases [0.03%]
大剂量脑转移瘤切除腔立体定向放射外科治疗I / II期临床试验研究
Daniella Klebaner,Erqi L Pollom,Elham Rahimy et al.
Daniella Klebaner et al.
Purpose: We performed a dose escalation trial of hypofractionated stereotactic radiosurgery (SRS) to determine the maximum tolerated dose (MTD) of 3-fraction SRS for brain metastases resection cavities. ...